Vera Therapeutics VERA EBITDA

EBITDA at other companies

Vertex PharmaceuticalsVRTX

$1.19B+76.0%

Travere Therapeutics, Inc.TVTX

-$11.7M+60.8%

Aurinia PharmaceuticalsAUPH

$51.18M+105%

Climb Bio, Inc.CLYM

-$15.17M+34.1%

Jade BiosciencesJBIO

-$43.44M-85.8%

Viridian Therapeutics, Inc.VRDN

-$126.15M-18.3%

FAQ

What is Vera Therapeutics's EBITDA?

Vera Therapeutics (VERA) reported EBITDA of -$124.99M in Q1 2026.

How has Vera Therapeutics's EBITDA changed year-over-year?

Vera Therapeutics's EBITDA decreased by 118.9% year-over-year, from -$57.11M to -$124.99M.

What is the long-term trend for Vera Therapeutics's EBITDA?

Over 4 years (2021 to 2025), Vera Therapeutics's EBITDA has grown at a 74.2% compound annual growth rate (CAGR), from -$34.23M to -$315.01M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.